This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Glomerulonephritis
  • /
  • Complement activation in IgA nephropathy
Journal

Complement activation in IgA nephropathy

Read time: 1 mins
Published:30th Sep 2021
Author: Medjeral-Thomas NR, Cook HT, Pickering MC.
Availability: Free full text
Ref.:Semin Immunopathol. 2021 Oct;43(5):679-690.
DOI:10.1007/s00281-021-00882-9
Complement activation in IgA nephropathy


IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.


Read abstract on library site    Access full article